Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 2 Completed 30 enrolled AstraZeneca Parexel · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).

Timeline

Start: 2021-11-03
Primary completion: 2023-08-22
Completion: 2024-10-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capivasertib	Small molecule	—	Oral

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Summary

Timeline

Drugs

Indications